Compared with the CAR NK cells singly targeting EGFR or EGFRvIII, the dual‐specific CAR NK cells showed a superior antitumor effect in GBM xenograft mice, demonstrating that dual‐targeted CAR cell therapy is a promising strategy to reduce the risk of immune escape.129. The gene discussed is EGFR; the disease is glioblastoma.